Anteris Technologies to present on one-year outcomes for DurAVR THV

Anteris Technologies (AVR) announced that one-year clinical outcomes with the DurAVR Transcatheter Heart Valve will be presented by Rishi Puri MD PhD, at TCT 2025 – The 37th Annual Transcatheter Cardiovascular Therapeutics Conference, taking place in San Francisco, California, October 25-28, 2025. An oral presentation is scheduled for Monday, October 27 in the Innovation Theater, Hall E, Exhibition Level, Moscone North, Moscone Center, as part of “Innovation Session 11: Emerging Concepts and Technologies in TAVR”, entitled “The DurAVR Biomimetic TAVR System in Patients with Small Aortic Annuli: One-Year Clinical and Hemodynamic Outcomes”. The presentation focuses on one-year clinical outcomes for the DurAVR THV in symptomatic severe aortic stenosis patients with small aortic annuli. The clinical outcomes observed to date in over 100 patients implanted with the DurAVR THV will be further evaluated in the Company’s global pivotal trial. The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR THV compared to commercially available transcatheter aortic valve replacements in the treatment of severe aortic stenosis.